The hormone receptor (HR)-positive, human epithelial receptor 2 (HER2)-negative subtype accounts for approximately 70% of all breast cancer cases and is mostly diagnosed in early, resectable stages [2]. Here, ERBB2 is linked to breast carcinoma.